[{"id":"ba5a9900-5311-4370-977a-05b3928feb30","acronym":"","url":"https://clinicaltrials.gov/study/NCT04847453","created_at":"2021-04-19T12:52:34.348Z","updated_at":"2025-02-25T13:49:06.836Z","phase":"Phase 1","brief_title":"Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis","source_id_and_acronym":"NCT04847453","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • MCL1 • BCL2L1 • SDC1 • BAX","pipe":" | ","alterations":" Chr t(11;14)","tags":["BCL2 • MCL1 • BCL2L1 • SDC1 • BAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Ninlaro (ixazomib) • dexamethasone • Hemady (dexamethasone tablets)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 08/03/2022","start_date":" 08/03/2022","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-20"},{"id":"be0a0acb-715b-4bf3-8af3-8a6314e2a31f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06514261","created_at":"2025-02-25T20:15:15.595Z","updated_at":"2025-02-25T20:15:15.595Z","phase":"Phase 1","brief_title":"Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML","source_id_and_acronym":"NCT06514261","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • BCL2 • NF1 • MCL1 • BCL2L1 • BAX","pipe":"","alterations":" ","tags":["TP53 • BCL2 • NF1 • MCL1 • BCL2L1 • BAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • iadademstat (ORY-1001)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 12/18/2024","start_date":" 12/18/2024","primary_txt":" Primary completion: 09/16/2026","primary_completion_date":" 09/16/2026","study_txt":" Completion: 09/16/2026","study_completion_date":" 09/16/2026","last_update_posted":"2025-01-16"},{"id":"450e3be9-d027-4ab5-af42-c83f193b46b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06134388","created_at":"2023-11-19T12:16:06.655Z","updated_at":"2024-07-02T16:35:28.801Z","phase":"Phase 3","brief_title":"Sulfasalazine in Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06134388","lead_sponsor":"Tanta University","biomarkers":" BCL2 • BAX","pipe":"","alterations":" ","tags":["BCL2 • BAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-11-18"},{"id":"97d535c2-613d-4bea-bd1b-97d4e14f968f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02965703","created_at":"2021-01-18T14:34:35.708Z","updated_at":"2024-07-02T16:35:31.010Z","phase":"Phase 2","brief_title":"Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma","source_id_and_acronym":"NCT02965703","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BAX","pipe":"","alterations":" ","tags":["BCL2 • BAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 01/16/2018","start_date":" 01/16/2018","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2023-10-31"},{"id":"e92471d9-fc4e-4170-a0ba-e8d100dcff1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05456022","created_at":"2022-07-13T12:56:27.026Z","updated_at":"2024-07-02T16:36:07.358Z","phase":"Phase 2","brief_title":"Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line","source_id_and_acronym":"NCT05456022","lead_sponsor":"Cairo University","biomarkers":" BCL2 • BAX • GAPDH • ANXA5","pipe":" | ","alterations":" BCL2 expression • BAX expression","tags":["BCL2 • BAX • GAPDH • ANXA5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • BAX expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 1000000","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-07-13"},{"id":"8ecb7624-1e34-46a2-8e81-e407b465fc51","acronym":"","url":"https://clinicaltrials.gov/study/NCT00052611","created_at":"2021-01-18T00:05:52.353Z","updated_at":"2024-07-02T16:37:12.672Z","phase":"Phase 2","brief_title":"Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia","source_id_and_acronym":"NCT00052611","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BCL2 • AKT1 • BAX • PTGS2 • CD31 • PECAM1","pipe":" | ","alterations":" BCL2 expression • BAX expression • CD31 expression • PTGS2 expression • VEGFA expression","tags":["BCL2 • AKT1 • BAX • PTGS2 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • BAX expression • CD31 expression • PTGS2 expression • VEGFA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 06/01/2002","start_date":" 06/01/2002","primary_txt":" Primary completion: 03/01/2005","primary_completion_date":" 03/01/2005","study_txt":" Completion: 03/01/2005","study_completion_date":" 03/01/2005","last_update_posted":"2018-03-29"},{"id":"2d0771db-8404-4a3a-899d-84b485cc6aea","acronym":"","url":"https://clinicaltrials.gov/study/NCT00896857","created_at":"2021-01-18T03:26:21.012Z","updated_at":"2024-07-02T16:37:24.366Z","phase":"","brief_title":"Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer","source_id_and_acronym":"NCT00896857","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" BCL2 • BCL2L1 • BAX","pipe":" | ","alterations":" BAX expression","tags":["BCL2 • BCL2L1 • BAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAX expression"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 04/01/2004","start_date":" 04/01/2004","primary_txt":" Primary completion: 02/01/2008","primary_completion_date":" 02/01/2008","study_txt":" Completion: 02/01/2008","study_completion_date":" 02/01/2008","last_update_posted":"2017-03-15"}]